Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience
Background: Epithelial ovarian cancer (EOC) is the commonest malignancy involving the ovaries. Maximum surgical cytoreduction (MCR) followed by adjuvant taxane-platinum chemotherapy are the standard of care treatments. Aims: To study treatment outcomes of EOC patients that were maximally cyto-reduce...
Saved in:
Published in | Asian Pacific journal of cancer prevention : APJCP Vol. 16; no. 16; pp. 7237 - 7242 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | Korean |
Published |
2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Epithelial ovarian cancer (EOC) is the commonest malignancy involving the ovaries. Maximum surgical cytoreduction (MCR) followed by adjuvant taxane-platinum chemotherapy are the standard of care treatments. Aims: To study treatment outcomes of EOC patients that were maximally cyto-reduced and received adjuvant paclitaxel-carboplatin (PC) chemotherapy. Materials and Methods: This retrospective cohort study included 174 patients with EOC treated at the Egyptian National Cancer Institute between 2006 and 2010. For inclusion, they should have had undergone MCR with no-gross residual followed by adjuvant PC chemotherapy. MCR was total abdominal hysterectomy/bilateral salpingo-oophorectomy [TAH/BSO] or unilateral salpingo-oophorectomy [USO] plus comprehensive staging. Results: The median age was 50 years. Most patients were married (97.1%), had offspring (92.5%), were postmenopausal (53.4%), presented with abdominal/pelvic pain and swelling (93.7%), had tumors involving both ovaries (45.4%) without extra-ovarian extension i.e. stage I (55.2%) of serous histology (79.9%) and grade II (87.4%). TAH/BSO was performed in 97.7% of cases. A total of 1,014 PC chemotherapy cycles were administered and were generally tolerable with 93.7% completing 6 cycles. Alopecia and numbness were the commonest adverse events. The median follow up period was 42 months. The 2-year rates for disease free survival (DFS) and overall survival (OS) were 70.7% and 94.8%, respectively. The respective 5-year rates were 52.6% and 81.3%. Advanced stage and high-grade were significantly associated with poor DFS and OS (p<0.001). Age >65 years was associated with poor OS (p =0.008). Using Cox-regression, stage was independent predictor of poor DFS and OS. Age was an independent predictor of poor OS. |
---|---|
AbstractList | Background: Epithelial ovarian cancer (EOC) is the commonest malignancy involving the ovaries. Maximum surgical cytoreduction (MCR) followed by adjuvant taxane-platinum chemotherapy are the standard of care treatments. Aims: To study treatment outcomes of EOC patients that were maximally cyto-reduced and received adjuvant paclitaxel-carboplatin (PC) chemotherapy. Materials and Methods: This retrospective cohort study included 174 patients with EOC treated at the Egyptian National Cancer Institute between 2006 and 2010. For inclusion, they should have had undergone MCR with no-gross residual followed by adjuvant PC chemotherapy. MCR was total abdominal hysterectomy/bilateral salpingo-oophorectomy [TAH/BSO] or unilateral salpingo-oophorectomy [USO] plus comprehensive staging. Results: The median age was 50 years. Most patients were married (97.1%), had offspring (92.5%), were postmenopausal (53.4%), presented with abdominal/pelvic pain and swelling (93.7%), had tumors involving both ovaries (45.4%) without extra-ovarian extension i.e. stage I (55.2%) of serous histology (79.9%) and grade II (87.4%). TAH/BSO was performed in 97.7% of cases. A total of 1,014 PC chemotherapy cycles were administered and were generally tolerable with 93.7% completing 6 cycles. Alopecia and numbness were the commonest adverse events. The median follow up period was 42 months. The 2-year rates for disease free survival (DFS) and overall survival (OS) were 70.7% and 94.8%, respectively. The respective 5-year rates were 52.6% and 81.3%. Advanced stage and high-grade were significantly associated with poor DFS and OS (p<0.001). Age >65 years was associated with poor OS (p =0.008). Using Cox-regression, stage was independent predictor of poor DFS and OS. Age was an independent predictor of poor OS. |
Author | Helal, Amany Mohamed Elbassuiony, Mohamed A Elsayed, Abeer Mohamed Nassar, Hanan Ramadan Zeeneldin, Ahmed A Moneer, Manar M Ismail, Yahia Mahmoud |
Author_xml | – sequence: 1 fullname: Nassar, Hanan Ramadan – sequence: 2 fullname: Zeeneldin, Ahmed A – sequence: 3 fullname: Helal, Amany Mohamed – sequence: 4 fullname: Ismail, Yahia Mahmoud – sequence: 5 fullname: Elsayed, Abeer Mohamed – sequence: 6 fullname: Elbassuiony, Mohamed A – sequence: 7 fullname: Moneer, Manar M |
BookMark | eNqNzc1Og0AUhuGJqYmovYezcUnCzwCNu4bQ-BPFRRfumlM4bY8OM2RmqHArXq2YeAGuvs2X97kWC200XYggkUUeFnnyvhBBnMVpWKT56kosneN9JGWRRrmUgfjeWkLfkfZQD74xHTkwB6h69idSjArqM1pGDSXqhqyDjVHKfLE-wguO3A0dlJM3ltqh8Ww0oG5h3X4MZ5ybb9go9jiSCku0e9Mr9Dy3TtSZGbDYT_dQHafe_xKv5SNUY0-WabZuxeUBlaPl396Iu021LR_CT3aed7p1ave0fq6TKM5SGecrmSVZkqf__f0AkAFdGw |
ContentType | Journal Article |
DBID | JDI |
DEWEY | 616.994 |
DatabaseName | KoreaScience |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience |
EISSN | 2476-762X |
EndPage | 7242 |
ExternalDocumentID | JAKO201534168452526 |
GroupedDBID | --- .UV 23N 2WC 53G 5GY 9ZL ADBBV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV C1A DIK E3Z EBS EJD F5P FRJ GROUPED_DOAJ GX1 HYE JDI OK1 RPM TR2 W2D WOW |
ID | FETCH-kisti_ndsl_JAKO2015341684525263 |
ISSN | 1513-7368 |
IngestDate | Fri Dec 22 12:04:07 EST 2023 |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Keywords | adjuvant chemotherapy Egypt, National Cancer Institute Ovarian neoplasms epithelial cytoreduction |
Language | Korean |
LinkModel | OpenURL |
MergedId | FETCHMERGED-kisti_ndsl_JAKO2015341684525263 |
Notes | KISTI1.1003/JNL.JAKO201534168452526 |
OpenAccessLink | http://click.ndsl.kr/servlet/LinkingDetailView?cn=JAKO201534168452526&dbt=JAKO&org_code=O481&site_code=SS1481&service_code=01 |
ParticipantIDs | kisti_ndsl_JAKO201534168452526 |
PublicationCentury | 2000 |
PublicationDate | 2015 |
PublicationDateYYYYMMDD | 2015-01-01 |
PublicationDate_xml | – year: 2015 text: 2015 |
PublicationDecade | 2010 |
PublicationTitle | Asian Pacific journal of cancer prevention : APJCP |
PublicationTitleAlternate | Asian Pacific journal of cancer prevention : APJCP |
PublicationYear | 2015 |
SSID | ssib044730644 ssib007832521 ssj0045875 |
Score | 4.124821 |
Snippet | Background: Epithelial ovarian cancer (EOC) is the commonest malignancy involving the ovaries. Maximum surgical cytoreduction (MCR) followed by adjuvant... |
SourceID | kisti |
SourceType | Open Access Repository |
StartPage | 7237 |
Title | Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience |
URI | http://click.ndsl.kr/servlet/LinkingDetailView?cn=JAKO201534168452526&dbt=JAKO&org_code=O481&site_code=SS1481&service_code=01 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF1FPSAuVflSaaGaA5wqV8Xe2E5vkZUqBCXhUKTApdr1h5w2jqvULoWfwo_iNzGzu3Y2KALKxYpW0dreeR6_mZ15ZuyNJA05v5s4vfBUOFz2PCfMMu546CaFQH4iY0rojyf-8BMfzbqzTuenVbVUV_Ik_r61r-R_rIpjaFfqkn2AZdtJcQB_o33xiBbG47_ZuK0Sn9YVnkALyA5uqM9iQanw6R2GwvgER2Tb1e3xOVq9_ErZgbG4nxd1cRx9w6Cb5Furpi65n1zVSK8rJJcxKXjfpwsnEitZ3lDZHM6Vp4Vp21JqUQP6kBmdZBK9t5STbdbbV52apv7PFquI1XWRUEFTdqkSlR9HUdt2NkF2r4vAh2JJ-w2iEMka0l8wDk9pA005uRzf7evsLL5Sha5BKKiqYVzmojC9XOphKIROgH8W-VzgiuRFWSd2GkS3gDY--53nBJ7-Os9JqsZcHvgO-vnZhqP3bUDbbjtwtfKMoQCBqxW_NuW5f3tttsWMo_6HKV0R8gE_pG1ilxTgSbXIivDJvQXoPS22xHlA4R9viAPvhkoXur0fjJcoiJhbhOdij-2aSAX6GnZPWOe6fMoejU0txjP2o0UfNOiDMoM1-sCgDwz6oEUfGPTBBvoA0QcN-mA7-sBG3xk02APEHqyx95y9PR9cRENH3djlMrldXG5ZP-8F21mWy3SfgeBZFnIkzZlHWpa4RnEv9HvSPe0KKWPvJTv681wHf_vDIXtMIzqv9ortVKs6fY1Ms5JHyn6_AM2ghzg |
link.rule.ids | 230,315,786,790,891,4043 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+Outcomes+of+Epithelial+Ovarian+Cancers+Following+Maximum+Cytoreduction+and+Adjuvant+Paclitaxel-Carboplatin+Chemotherapy%3A+Egyptian+NCI+Experience&rft.jtitle=Asian+Pacific+journal+of+cancer+prevention+%3A+APJCP&rft.au=Nassar%2C+Hanan+Ramadan&rft.au=Zeeneldin%2C+Ahmed+A&rft.au=Helal%2C+Amany+Mohamed&rft.au=Ismail%2C+Yahia+Mahmoud&rft.date=2015&rft.issn=1513-7368&rft.eissn=2476-762X&rft.volume=16&rft.issue=16&rft.spage=7237&rft.epage=7242&rft.externalDBID=n%2Fa&rft.externalDocID=JAKO201534168452526 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1513-7368&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1513-7368&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1513-7368&client=summon |